Certara, Inc. (CERT)

NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-23

$10.33+2.38%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Certara, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

+1.8%

+10% or more+5%0%−5%−10% or less

0.39 → 0.40 EPS · FY ending Dec 31, 2027 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	94.77M
EPS	—	0.098
FY 2026 · Annual
Revenue	$395M–$405M	379.07M
EPS	$0.31–$0.36non-GAAP	0.34
Revenue growth	0%–4%	—
FY 2027 · Annual
Revenue	—	388.8M
EPS	—	0.398

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Stable leadership after CFO transition	A supporting condition in Certara, Inc.'s published investment case. The stated target is No further key executive departures in next 4 quarters.	Under Pressure	Additional key executives leave within next 4 quarters	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Adjusted EBITDA margin near 30% to 32%	Profit margins should stay near 30% to 32%.	Intact	Margin falls below 30% in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA margin was 32% in 2025 and management expects approximately 29% to 31% margin for continuing operations in 2026 excluding the divested business. The margin guidance reflects a slight decline but remains within the targeted range, indicating management is maintaining cost discipline amid restructuring. Delivery assessment Oct 24, 2026
Revenue growth of 0% to 4% excluding divested business	A primary condition in Certara, Inc.'s published investment case. The stated target is 0% to 4% growth YoY.	Under Pressure	Revenue growth falls below 0% in FY26	Revenue growth: -10.81% FY2026-Q2; GAAP. Published target: 0% to 4% growth YoY. Target period is not explicitly aligned with this observation. Source published Aug 4, 2026-10.805202 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 33ef6975-4fdf-4837-bd81-4b78144962b3. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue was $418.8M in 2025 and continuing operations revenue guidance for 2026 is $367M to $382M reflecting 0% to 4% growth excluding the divested Regulatory and Medical Writing business. Management has consistently reaffirmed this growth range, and the trajectory is delivering with modest growth in software offsetting services declines. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.40

$0.41 → $0.40 · observed estimates

FY2027 revenue$0.39B

$0.41B → $0.39B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.41	$405,471,360	11 / 11
2026-07-25	$0.41	$405,471,360	11 / 11
2026-07-26	$0.41	$405,471,360	11 / 11
2026-07-27	$0.41	$405,471,360	11 / 11
2026-07-28	$0.41	$405,471,360	11 / 11
2026-07-29	$0.41	$405,471,360	11 / 11
2026-07-30	$0.41	$405,471,360	11 / 11
2026-07-31	$0.42	$406,065,917	6 / 8
2026-08-01	$0.41	$405,471,360	11 / 11
2026-08-02	$0.41	$405,471,360	11 / 11
2026-08-03	$0.41	$405,471,360	11 / 11
2026-08-04	$0.41	$405,471,360	11 / 11
2026-08-05	$0.42	$406,065,917	5 / 8
2026-08-06	$0.42	$406,065,917	5 / 8
2026-08-07	$0.40	$391,498,596	6 / 8
2026-08-08	$0.40	$391,498,630	11 / 11
2026-08-09	$0.40	$391,498,630	11 / 11
2026-08-10	$0.40	$391,498,630	11 / 11
2026-08-11	$0.40	$391,498,596	6 / 8
2026-08-12	$0.40	$391,498,596	6 / 8
2026-08-13	$0.40	$391,498,630	11 / 11
2026-08-14	$0.40	$391,498,596	6 / 8
2026-08-15	$0.40	$391,498,596	6 / 8
2026-08-16	$0.40	$391,498,596	6 / 8
2026-08-17	$0.40	$391,498,596	6 / 8
2026-08-18	$0.40	$391,498,596	6 / 8
2026-08-19	$0.40	$391,498,596	6 / 8
2026-08-20	$0.39	$389,554,266	6 / 8
2026-08-21	$0.39	$389,554,266	6 / 8
2026-08-22	$0.39	$389,554,266	6 / 8
2026-08-23	$0.39	$389,554,266	6 / 8
2026-08-24	$0.39	$389,554,266	6 / 8
2026-08-25	$0.39	$389,554,266	6 / 8
2026-08-26	$0.39	$389,554,266	6 / 8
2026-08-27	$0.39	$389,554,266	6 / 8
2026-08-28	$0.39	$389,554,266	6 / 8
2026-08-29	$0.39	$389,554,266	6 / 8
2026-08-30	$0.39	$389,554,266	6 / 8
2026-08-31	$0.39	$389,554,266	6 / 8
2026-09-01	$0.39	$389,554,266	6 / 8
2026-09-02	$0.39	$389,554,266	6 / 8
2026-09-03	$0.39	$389,554,266	6 / 8
2026-09-04	$0.39	$389,554,266	6 / 8
2026-09-05	$0.39	$389,554,266	6 / 8
2026-09-06	$0.39	$389,554,266	6 / 8
2026-09-07	$0.39	$389,554,266	6 / 8
2026-09-08	$0.39	$389,554,266	6 / 8
2026-09-09	$0.39	$389,554,266	6 / 8
2026-09-10	$0.39	$389,554,266	6 / 8
2026-09-11	$0.39	$389,554,266	6 / 8
2026-09-12	$0.39	$389,554,266	6 / 8
2026-09-13	$0.39	$389,554,266	6 / 8
2026-09-14	$0.39	$389,554,266	6 / 8
2026-09-15	$0.39	$389,554,266	6 / 8
2026-09-16	$0.39	$389,554,266	6 / 8
2026-09-17	$0.39	$389,554,266	6 / 8
2026-09-18	$0.39	$389,554,266	6 / 8
2026-09-19	$0.39	$389,554,266	6 / 8
2026-09-20	$0.39	$389,554,266	6 / 8
2026-09-21	$0.39	$389,554,266	6 / 8
2026-09-22	$0.39	$389,554,266	6 / 8
2026-09-23	$0.39	$389,554,266	6 / 8
2026-09-24	$0.39	$389,554,266	6 / 8
2026-09-25	$0.39	$389,554,266	6 / 8
2026-09-26	$0.39	$389,554,266	6 / 8
2026-09-27	$0.39	$389,554,266	6 / 8
2026-09-28	$0.39	$389,554,266	6 / 8
2026-09-29	$0.39	$389,554,266	6 / 8
2026-09-30	$0.39	$389,554,266	6 / 8
2026-10-01	$0.39	$389,545,598	6 / 9
2026-10-02	$0.39	$389,545,598	6 / 9
2026-10-03	$0.39	$389,545,598	6 / 9
2026-10-04	$0.39	$389,545,598	6 / 9
2026-10-05	$0.39	$389,545,598	6 / 9
2026-10-06	$0.39	$389,545,598	6 / 9
2026-10-07	$0.39	$389,545,598	6 / 9
2026-10-08	$0.39	$389,545,598	6 / 9
2026-10-09	$0.39	$389,595,598	6 / 9
2026-10-10	$0.39	$389,595,598	6 / 9
2026-10-11	$0.39	$389,595,598	6 / 9
2026-10-12	$0.39	$389,595,598	6 / 9
2026-10-13	$0.39	$389,595,598	6 / 9
2026-10-14	$0.40	$388,537,265	6 / 9
2026-10-15	$0.40	$388,537,265	5 / 9
2026-10-16	$0.40	$388,537,265	5 / 8
2026-10-17	$0.40	$388,537,265	5 / 8
2026-10-18	$0.40	$389,145,598	5 / 8
2026-10-19	$0.40	$389,145,598	5 / 8
2026-10-20	$0.40	$388,799,765	5 / 8
2026-10-21	$0.40	$388,799,765	5 / 8
2026-10-22	$0.40	$388,799,765	5 / 8
2026-10-23	$0.40	$388,799,765	5 / 9
2026-10-24	$0.40	$388,799,765	5 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	5	8
2026-06-01	5	8
2026-07-01	4	8
2026-08-01	4	8
2026-09-01	4	9
2026-10-01	4	9

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 9 Hold · 0 Sell / Strong Sell

0 upgrades1 downgrades3 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSSep 30

$10.00New observation · no comparable prior

$0$5.50$11.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Stable leadership after CFO transitionPublished status: Under Pressure
Adjusted EBITDA margin near 30% to 32%Direct metric needs a verified mapping
Revenue growth of 0% to 4% excluding divested businessPublished status: Under Pressure

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-64.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Certara, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a restructuring and execution-dependent business with a cyclical sector backdrop, not yet a proven durable compounder. Its multi-year view is intact, but confidence is medium because the company remains loss-making and recent quarters have included earnings misses.

What's priced into Certara, Inc.

CERT’s valuation is expensive versus peers, while the evidence does not show the full combination of weak fundamentals and turbulent conditions being reflected in that valuation. Expectations and the valuation signal are broadly aligned, but the size of the expectations gap is not defined in plain terms by the evidence.

What the fundamentals likely do

Near term, management has reaffirmed 2026 continuing-operations revenue growth of 0% to 4%, with modest software growth offsetting services declines. Its margin outlook is slightly lower than the 2025 result, so cost discipline remains important, while the completed divestiture sharpens the focus on continuing operations. The next earnings report carries risk because of the recent run of misses, and a guidance cut would weaken the thesis.

What Certara, Inc. hinges on

Over the next few quarters, the key test is whether management delivers the reaffirmed growth range and maintains margins near its stated outlook. A weakening jobs report could add pressure through recession concerns, while continued strong results and higher guidance from healthcare peers could support the sector backdrop. The president transition is also a recent management change to watch, though the evidence gives no further detail on its effect.